New asthma drug shows promise in real-world greek study

NCT ID NCT05440656

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study followed 152 adults in Greece with severe eosinophilic asthma who were starting benralizumab, a medication that helps control severe asthma. Researchers measured not only standard asthma control but also quality of life, sleep, mood, and physical activity using wearable trackers over 48 weeks. The goal was to see how the drug works in routine care beyond just lung function.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEVERE EOSINOPHILIC ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma pulmonary eosinophilia T2-high asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Research Site

    Alexandroupoli, 68100, Greece

  • Research Site

    Athens, 11521, Greece

  • Research Site

    Athens, 11527, Greece

  • Research Site

    Athens, 12462, Greece

  • Research Site

    Athens, 15125, Greece

  • Research Site

    Athens, 17562, Greece

  • Research Site

    Corfu, 49100, Greece

  • Research Site

    Heraklion, 71500, Greece

  • Research Site

    Ioannina, 45500, Greece

  • Research Site

    Rio, 26504, Greece

  • Research Site

    Thessaloniki, 55535, Greece

  • Research Site

    Thessaloniki, 56429, Greece

  • Research Site

    Thessaloniki, 57010, Greece